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EDITORIAL
BRONCHIAL ASTHMA - PROBLEMS AND CHALLENGES
The prevalence of bronchial asthma, a major
public health problem is increasing world wide (1,2).
Asthma was found to be more prevalent among black
and poor American children (3). However, other studies
had not shown such racial differences (4,5). High
prevalence of asthma has been reported in urban areas
and low prevalence in rural communities (3,6).
prevalence of asthma is also found to be higher in boys
than in girls (7). Other risk factors for developing asthma
especially in children include exposure to environmental
tobacco smoke and air pollution, low birth weight, and
children of younger mothers (8). Several studies had
demonstrated increase in morbidity and mortality from
bronchial asthma (9). Over and under treatment of
asthma may be responsible for high mortality rates (10).
The increase in asthma deaths has been attributed to
regular use of b agonists that may lead to worsening of
asthma (11). The excess mortality from b agonists has
been demonstrated with fenoterol but not with salbutamol
(11,12). However, further long term studies are required
to settle this controversy. India is a subcontinent with
different geographic, racial, cultural and economic
groups. It is a pity that there are no well conducted studies
from India to know the exact prevalence of asthma and
its influence on various geographic, socio-economic and
racial factors. In this issue of the journal, Gupta provides
the clinical profile of the asthma as seen in eastern India
(13). Even though it is a hospital based study, it gives a
glimpse of the gravity of the problem. Therefore, there is
an urgent need for undertaking multicentric prevalence
studies in bronchial asthma in our country.
Until recently bronchospasm that results from
hyperresponsiveness of the lower airways to a multiplicity
of stimuli has been regarded as the main cause of airway
dysfunction in asthma. However, postmortem findings
in the airways of subjects dying of acute asthma had
shown widespread infiltration of inflammatory ceils
especially lymphocytes and eosinopils, desquamation
of epithelial cells and mucus hypersecretion (14).
Subsequently, studies utilising both bronchial biopsies
and bronchoalveolar lavages have identified cellular
infiltrations of the bronchial mucosa and submucosa by
eosinophils and other inflammatory cells even in patients
with mild stable asthma (15,16). Thus airway
inflammation is found in both fatal and mild forms of
asthma. Based on these studies, bronchial asthma is
now defined as a chronic persistent inflammatory disease
o f  t h e  a i r w a y s  ( 2 ) .  E l e c t r o n microscopic,
immunohistochemical and molecular biological
techniques used in the study of the cells and mediators
in the samples obtained by biopsies and lavages have
enabled us to better understand the
immunopathogenesis in bronchial asthma. Salvi and
Holgate have described in detail the recent developments
in immunopathogenesis of asthma in this issue (17).
Multiple cytokines have been implicated in asthma and
they are derived from a variety of cells including epithelial
cells. Future studies may unravel the role of epithelial
and endothelial barriers in regulating inflammatory
chemotactic responses including the role of adhesion
molecules. Studies are required to define the role of
inflammation in nocturnal asthma as conflicting results
are obtained in nocturnal asthma by BAL studies (18,19).
Respiratory infections commonly with viruses can
precipitate symptoms of wheezing in patients with asthma
especially in children and can induce airway
hyperresponsiveness in non-asthmatics (20,21).
However, the mechanism responsible for those reactions
following viral infections are not clear. Studies are also
essential to know how a single massive exposure to
irritant gases such as that occurred at Bhopal causes
asthma - like syndrome termed as reactive airways
dysfunction syndrome (22,23). Another area that requires
in depth study is the role of genetics in asthma as it has
been demonstrated that there is an increased frequency
of asthma and / or hyperresponsiveness in first degree
relatives of asthmatics (24).
The realization that inflammation is the key factor
in the pathogenesis of asthma, is reflected in the recent
trend in asthma therapy with emphasis on anti-
inflammatory drugs (2). Glucocorticosteroids are the
most potent antiinflammatory agents available for the
treatment of asthma. The systemic side effects of
corticosteroids can be reduced by delivering the drug by
inhaled route. Efficacy of inhaled glucocorticosteroids can
be enhanced by using a large volume spacer device.
Beclomethasone dipropionate, budesonide, fluticasone
propionate, triamcinolone acetonide and flunisolide are
available as inhaled glucocorticoid preparations. Sodium
cromoglycate and nedocromil sodium are other anti
inflammatory drugs. Inhaled corticosteroids upto 1000
ug per day may not cause adrenal suppression in adults
(25). However, in children, doses between 400 and 800
ug daily may retard growth. Fluticasone propionate is a
novel inhaled glucocorticoid with an improved efficacy
and safety profile compared to currently existing inhaled
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steroids (26). Fluticasone has the added advantage that
it has negligible oral bioavailability and hence unlike
beclomethasone and budesonide, there is little or no
systemic effect from swallowed portion of the drug (26).
However studies using this drug are required to assess
the safety profile in Indian patients. Some patients with
chronic severe asthma may require long term oral
maintenance treatment with steroids resulting in steroid
toxicity. Role of drugs such as low dose methotrexate
and cyclosporin is being evaluated in treatment of such
corticosteroid dependent asthmatics (27,28). In this issue
of the journal, Bedi gives an account of methotrexate in
the treatment of steroid dependent asthma (29).
However, these drugs should be used with caution under
strict supervision of a chest specialist.
T r e a t m e n t  o f  b r o n c h i a l  a s t h m a  w i t h
immunotherapy is controversial (30). There are only a
few well conducted studies to critically evaluate the
usefulness of immunotherapy. Even though there is a
poss ib i l i t y  tha t  immunotherapy  may b lock
allergeninduced inflammation, there are no proper
studies using BAL and bronchial biopsy to prove this
hypothesis. New drugs that are under development for
the treatment of asthma include VIP/VIP analogues,
selective phosphodiesterase (type Ill, IV, V) inhititors,
potassium channel openers, calcium antagonists,
nitrodilators (nitroprusside, atrial natriuretic peptide),
selective anticholinergics (M3-antagonists), mediator
antagonists (antagonists to leukotriene D4, 5-
Lipoxygenase and platelet activating factors), cytokine
inhibitors (IL-5 inhibitor), IgE suppressors (IL-4 inhibitors),
inhaled frusemide, cel l  adhesion blockers,
immunomodulators (cyclosporin A, FK 506, rapamycin)
etc (31). As n-3 fatty acids in fish oil inhibit prostaglandin
and leukotriene production from arachidonic acid, there
is a suggestion that fish oil may be useful in the treatment
of asthma (32,33). However, the role of dietary fish oil in
asthma is not yet proved (33).
Many National Thoracic societies have formulated
consensus reports for treatment of asthma (2,30). In a
country like ours, the long-term management of asthma
with inhaled corticosteroids and b stimulants is difficult
because of high costs and lack of patient education. Role
of cheaper drugs like theophylline should be defined
especially in our country. Therefore, we should develop
recommendations for management of asthma keeping
in mind the socioeconomic condition and literacy of
patients. Finally the question that is being asked by many
Patients for which we do not have an answer at present
is : can asthma be cured ? Let us hope that research in
bronchial asthma may ultimately lead to a cure in asthma.
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